Noninvasive type 2 diabetes screening: Superior sensitivity to fasting plasma glucose and A1C

Diabetes Care

Volumn 30, Issue 5, 2007, Pages 1120-1124

  Maynard, John D ^a   Rohrscheib, Mark ^b   Way, Jeffrey F ^c   Nguyen, Catriona M ^c   Ediger, Marwood N ^a  

^a VeraLight   (United States)

^b UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^c InLight Solutions Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C;

ADULT; AGED; ARTICLE; BLOOD EXAMINATION; CONTROLLED STUDY; DIET RESTRICTION; DISEASE CLASSIFICATION; FEMALE; FLUORESCENCE ANALYSIS; GLUCOSE BLOOD LEVEL; GLYCATION; HUMAN; IMPAIRED GLUCOSE TOLERANCE; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MEDICAL INSTRUMENTATION; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PREVALENCE; SCREENING TEST; SENSITIVITY AND SPECIFICITY; STATISTICAL SIGNIFICANCE;

ADULT; AGED; BLOOD GLUCOSE; CONTINENTAL POPULATION GROUPS; DIABETES MELLITUS, TYPE 2; ETHNIC GROUPS; FEMALE; GLUCOSE TOLERANCE TEST; GLYCOSYLATION END PRODUCTS, ADVANCED; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; SENSITIVITY AND SPECIFICITY; UNITED STATES;

EID: 34247574705     PISSN: 01495992     EISSN: 01495992     Source Type: Journal    
DOI: 10.2337/dc06-2377     Document Type: Article

References (26)

1. Centers for Disease Control and Prevention: National Diabetes Fact Sheet. Atlanta, GA, U.S. Department of Health and Human Services, 2005
2. Cowie CC, Rust KF, Byrd-Holt DD, Eberhardt MS, Flegal KM, Engelgau MM, Saydah SH, Williams DE, Geiss LS, Gregg EW: Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population: National Health And Nutrition Examination Survey 1999-2002. Diabetes Care 29:1263-1268, 2006
3. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM; Diabetes Prevention Program Research Group: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393-403, 2002
4. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M; Finnish Diabetes Prevention Study Group: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344:1343-50, 2001
5. DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators; Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, Hanefeld M, Hoogwerf B, Laakso M, Mohan V, Shaw J, Zinman B, Holman RR: Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial. Lancet 368:1096-1105, 2006
6. Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX, Hu ZX, Lin J, Xiao JZ, Cao HB, Liu PA, Jiang XG, Jiang YY, Wang JP, Zheng H, Zhang H, Bennett PH, Howard BV: Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the Da Qing IGT and Diabetes Study. Diabetes Care 20:537-544, 1997
7. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M; STOP-NIDDM Trail Research Group: Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomized trial. Lancet 359:2072-2077, 2002
8. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986, 1993
9. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853, 1998
10. Engelgau MM, Narayan KM, Herman WH: Screening for type 2 diabetes. Diabetes Care 23:1563-1580, 2000
11. Harris MI, Eastman RC: Early detection of undiagnosed diabetes mellitus: a US perspective. Diabete Metab Res Rev 16:230-236, 2001
12. Manley SM, Meyer LC, Neil HAW, Ross IS, Turner RC, Holman RR: UKPDS 6: Complications in newly diagnosed type 2 diabetic patients and their association with different clinical and biologic risk factors. Diabetes Res 13:1-11, 1990
13. 1c as markers of diabetic complications. Diabetes 48:870-880, 1999
14. Genuth S, Sun W, Cleary P, Sell DR, Dahms W, Malone J, Sivitz W, Monnier VM, the DCCT Skin Collagen Ancillary Study Group: Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications participants with type 1 diabetes. Diabetes 54:3103-3111, 2005
15. Meerwaldt R, Links TP, Graaff R, Hoogenberg K, Lefrandt JD, Baynes JW, Gans RO, Smit AJ: Increased accumulation of skin advanced glycation end-products precedes and correlates with clinical manifestation of diabetic neuropathy. Diabetologia 48:1637-1644, 2005
16. Monnier VM, Vishwanath V, Frank KE, Elmets CA, Dauchot P, Kohn RR: Relation between complications of type 1 diabetes mellitus and collagen-linked fluorescence. N Engl J Med 314:403-408, 1986
17. Hull EL, Ediger MN, Brown CD, Maynard JD, Johnson RD: Determination of a measure of a glycation end-product or disease state using tissue fluorescence. U.S. patent 7139598, 2006
18. Hull EL, Ediger MN, Unione AHT, Deemer EK, Stroman ML, Baynes JW: Noninvasive, optical detection of diabetes: model studies with porcine skin. Optics Express 12:4496-4510, 2004
19. Ediger MN, Fleming CM, Rohrscheib M, Way JF, Nguyen CM, Maynard JD: Noninvasive fluorescence spectroscopy for diabetes screening: a clinical case-control study.) Abstract presented at the Diabetes Technology Meeting, 11 November 2005, at the Hyatt Regency Hotel, San Francisco, California
20. Schatzkin A, Connor RJ, Taylor PR, Bunnag B: Comparing new and old screening tests when a reference procedure cannot be performed on all acreenees: example of automated cytometry for early detection of cervical cancer. Am J Epidemiol 125: 672-678, 1987
21. American Diabetes Association: Standards of Medical Care in Diabetes: 2006 (Position Statement). Diabetes Care 29 (Suppl. 1):S4-S42, 2006
22. Safety of laser products. Part 9. Compilation of maximum permissible exposure to incoherent optical radiation. International Electrotechnical Commission, 1999 (IEC/TR 60825-9:1999)
23. Kramer R: Chemometric Techniques for Quantitative Analysis. New York, Marcel Dekker, 1998
24. McLachlan GL: Discriminant Analysis and Statistical Pattern Recognition. New York, Wiley Interscience, 1992
25. Barriers to Chronic Disease Care in the United States of America: The Case of Diabetes and its Consequences. Yale University Schools of Public Health and Medicine and the Institute for Alternative Futures, 2005
26. Hogan P, Dall T, Nikolov P: Economic costs of diabetes in the U.S. in 2002. Diabetes Care 26:917-932, 2003